Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
Stock Information for NanoViricides Inc.
Loading
Please wait while we load your information from QuoteMedia.